A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
Phase 1
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: UB-612
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- United Biomedical Inc., Asia
- Registration Number
- NCT05167253
A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: UB-612
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- United Biomedical Inc., Asia
- Target Recruit Count
- 50
- Registration Number
- NCT04967742
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- Biological: PlaceboBiological: UB-612
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- United Biomedical Inc., Asia
- Target Recruit Count
- 3877
- Registration Number
- NCT04773067
- Locations
- 🇨🇳
Far Eastern Memorial Hospital, New Taipei City, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: UB-612
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- United Biomedical Inc., Asia
- Target Recruit Count
- 60
- Registration Number
- NCT04545749
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
© Copyright 2025. All Rights Reserved by MedPath